

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of September 2023

	30.09.2023	31.12.2022
	<i>BGN'000</i>	<i>BGN'000</i>
ASSETS		
Non-current assets		
Property, plant and equipment	34 486	35 319
Intangible assets	3 705	3 761
Investments in subsidiaries	19	19
Trade receivables	5 076	5 076
Total non-current assets	43 286	44 175
Current assets		
Inventories	12 129	13 480
Trade and other receivables	66 400	62 056
Current corporate income tax	-	27
Cash and cash equivalents	70	126
Total current assets	78 599	75 689
Total assets	121 885	119 864
LIABILITIES		
Equity		
Share capital	84 500	84 500
Reserves	12 782	12 498
Retained earnings	8 711	4 591
Total	105 993	101 589
Non-current liabilities		
Long-term loans	861	1 399
Deferred tax liabilities	1 042	1 042
Retirement benefit obligations	191	191
Total non-current liabilities	2 094	2 632
Current liabilities		
Trade and other liabilities	2 948	5 079
Short-term loans	9 788	9 785
Current portion of long-term loans	631	620
Other tax liabilities	431	159
Total current liabilities	13 798	15 643
Total liabilities	15 892	18 275
Total equity and liabilities	121 885	119 864

Date of preparation: 25.10.2023

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of September 2023

	30.09.2023	30.09.2022
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	39 076	32 572
Other income	64	576
Total income	39 140	33 148
Carrying amount of goods sold	(775)	(614)
Changes in inventories of finished products and work in progress	(509)	276
Materials and services	(24 922)	(21 926)
Personnel expenses	(4 773)	(4 144)
Depreciation / amortisation expenses	(2 198)	(2 691)
Other expenses	(775)	(320)
Finance income	46	23
Finance costs	(480)	(354)
Total expenses	(34 386)	(29 750)
Profit before taxation	4 754	3 398
Corporate income tax expense	(350)	(270)
Profit/Loss for the period	4 404	3 128
Total comprehensive income for the period	4 404	3 128
Earnings per share / in BGN per 1 share /	0.05	0.04

Date of preparation: 25.10.2023

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....


/B. Georgiev/


Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 30 of September 2023

	30.09.2023	30.09.2022
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	24 559	22 469
Payments to suppliers of materials, goods and services	(13 077)	(13 014)
Payments to personnel	(4 462)	(4 260)
Foreign currency exchange gains/losses	(20)	(42)
Payments of interest and dividends	(323)	(355)
Other proceeds / payments	(4 359)	(3 605)
<i>Net cash flows</i>	2 318	1 193
Cash flows from investing activities		
Payments on non-current assets acquired	(1 605)	(659)
<i>Net cash flows</i>	(1 605)	(659)
Cash flows from financial activities		
Proceeds from loans	357	151
Payments on loans	(360)	(149)
Payment of interest, dividends	(375)	(167)
Payments on finance lease	(391)	(391)
<i>Net cash flows</i>	(769)	(556)
Change in cash and cash equivalents		
	(56)	(22)
Cash and cash equivalents at the beginning of the period	126	40
Cash and cash equivalents at the end of the period	70	18

Date of preparation: 25.10.2023

Sofia

Prepared by:.....

 / P. Moneva /

Executive
 Director:.....

 /B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of September 2023

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2022	84 500	4 375	8 007	1 940	98 822
Profit/loss for the period				2 791	2 791
Other comprehensive income		(24)			(24)
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		(24)		2 791	2 767
Issue of shares by the owners			140	(140)	
Dividends accrued			140	(140)	
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period					
Balance as of 31.12.2022	84 500	4 351	8 147	4 591	101 589
Balance as of 01.01.2023	84 500	4 351	8 147	4 591	101 589
Profit/loss for the period				4 404	4 404
Other comprehensive income					
Total comprehensive income				4 404	4 404
Issue of shares by the owners			284	(284)	
Total amount of income and expenses recognised during the period			284	(284)	
Balance as of 30.09.2023	84 500	4 351	8 431	8 711	105 993

Date of preparation: 25.10.2023
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev/